Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin effects

被引:0
|
作者
Weber, AA
Liesener, S
Schanz, A
Hohlfeld, T
Schrör, K
机构
[1] Univ Dusseldorf, Inst Pharmakol, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Klin Pharmakol, D-40225 Dusseldorf, Germany
关键词
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The present study investigates the effects of aspirin (100 mg every second day for 14 days) on platelet function in nine healthy non-smokers and in nine healthy habitual smokers, There was a significantly (P<0.05) stronger inhibition of collagen (0.61 mu g/ml)- and ADP (2 mu M)-induced platelet aggregation by aspirin in smokers as compared to non-smokers. This difference occurred in the presence of an almost complete (>95%) inhibition of thromboxane A(2) (TXA(2)) synthesis in both groups, The platelet capacity to generate TXA(2) in vitro was significantly reduced in smokers, urinary excretion of TXA(2), however, was significantly increased. Thus, the better susceptibility of smokers to anti-aggregatory effects of aspirin is very likely to be related to a chronic smoking-induced alteration of platelet TXA(2) system. Cessation of smoking should, therefore, be encouraged.
引用
收藏
页码:177 / 182
页数:6
相关论文
共 48 条
  • [1] THROMBOXANE A2, PROSTACYCLIN AND ASPIRIN - EFFECTS ON VASCULAR TONE AND PLATELET-AGGREGATION
    SMITH, JB
    ARAKI, H
    LEFER, AM
    CIRCULATION, 1980, 62 (06) : 19 - 25
  • [2] Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2
    Armstrong, P. C. J.
    Truss, N. J.
    Ali, F. Y.
    Dhanji, A. A.
    Vojnovic, I.
    Zain, Z. N. M.
    Bishop-Bailey, D.
    Paul-Clark, M. J.
    Tucker, A. T.
    Mitchell, J. A.
    Warner, T. D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (11) : 1933 - 1943
  • [3] Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin
    Pulcinelli, FM
    Riondino, S
    Celestini, A
    Pignatelli, P
    Trifirò, E
    Di Renzo, L
    Violi, F
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (12) : 2784 - 2789
  • [4] INHIBITION OF PROSTACYCLIN AND PLATELET THROMBOXANE A2 AFTER LOW-DOSE ASPIRIN
    PRESTON, FE
    WHIPPS, S
    JACKSON, CA
    FRENCH, AJ
    WYLD, PJ
    STODDARD, CJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (02): : 76 - 79
  • [5] PLATELET AGGREGABILITY, THROMBOXANE A2 AND MALONALDEHYDE FORMATION FOLLOWING ADMINISTRATION OF ASPIRIN TO MAN
    SZCZEKLIK, A
    GRYGLEWSKI, RJ
    GRODZINSKA, L
    MUSIAL, J
    SERWONSKA, M
    MARCINKIEWICZ, E
    THROMBOSIS RESEARCH, 1979, 15 (3-4) : 405 - 413
  • [6] Targeting the urine and plasma determinants of thromboxane A2 metabolism in detection of aspirin effectiveness
    Dobaczewski, Marcin
    Nocun, Marek
    Zavodnik, Ilya
    Ulicna, Olga
    Lapshina, Elena
    Zavodnik, Leu
    Golanski, Jacek
    Kamilerczak, Piotr
    Durackova, Zdenka
    Kostka, Barbara
    Markuszewski, Leszek
    Watala, Cezary
    BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (05) : 421 - 428
  • [7] Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease
    Santos, M. T.
    Valles, J.
    Lago, A.
    Tembl, J.
    Sanchez, E.
    Moscardo, A.
    Cosin, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (04) : 615 - 621
  • [8] EFFECTS OF OXYFEDRINE ON PLATELET THROMBOXANE A2 AND AORTA PROSTACYCLINS FORMATIONS
    FU, JM
    LI, ZX
    SHI, S
    ACTA PHARMACOLOGICA SINICA, 1988, 9 (05): : 433 - 437
  • [9] Evaluation of platelet function and thromboxane A2 production in aspirin-treated patients with essential thrombocythemia
    Lussana, F.
    Femia, E. A.
    Pugliano, M.
    Podda, G.
    Razzari, C.
    Maugeri, N.
    Lecchi, A.
    Motta, G.
    Caberlon, S.
    Gerli, G.
    Cattaneo, M.
    THROMBOSIS RESEARCH, 2012, 129 : S157 - S158
  • [10] Why are some individuals resistant to the cardioprotective effects of aspirin?: Could it be thromboxane A2?
    Halushka, MK
    Halushka, PV
    CIRCULATION, 2002, 105 (14) : 1620 - 1622